A M Jubb

Summary

Publications

  1. doi request reprint Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 60:740-7. 2012
  2. pmc Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
    A M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Level 4 Academic Block, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
    Br J Cancer 104:1877-81. 2011
  3. doi request reprint Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Lancet Oncol 11:1172-83. 2010
  4. ncbi request reprint Predicting benefit from anti-angiogenic agents in malignancy
    Adrian M Jubb
    Academic Unit of Pathology, Leeds Institute for Molecular Medicine, University of Leeds, UK
    Nat Rev Cancer 6:626-35. 2006
  5. ncbi request reprint Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia
    A M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    Oncogene 25:3445-57. 2006
  6. ncbi request reprint Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
    Adrian M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    J Clin Oncol 24:217-27. 2006
  7. ncbi request reprint EphB2 is a prognostic factor in colorectal cancer
    Adrian M Jubb
    Department of Pathology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 11:5181-7. 2005
  8. pmc Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours
    A M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA94080, USA
    J Clin Pathol 57:504-12. 2004
  9. ncbi request reprint Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization
    A M Jubb
    Department of Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Pathol 200:577-88. 2003
  10. pmc Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
    A M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Br J Cancer 101:1749-57. 2009

Collaborators

Detail Information

Publications17

  1. doi request reprint Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 60:740-7. 2012
    ..The aims of this study were to characterize the expression of Dll4 and Jag1 in primary glioblastomas...
  2. pmc Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
    A M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Level 4 Academic Block, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
    Br J Cancer 104:1877-81. 2011
    ..The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases...
  3. doi request reprint Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Lancet Oncol 11:1172-83. 2010
    ..Many questions relating to these and other surrogate biomarkers, however, remain unanswered and their clinical usefulness has yet to be proven...
  4. ncbi request reprint Predicting benefit from anti-angiogenic agents in malignancy
    Adrian M Jubb
    Academic Unit of Pathology, Leeds Institute for Molecular Medicine, University of Leeds, UK
    Nat Rev Cancer 6:626-35. 2006
    ....
  5. ncbi request reprint Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia
    A M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    Oncogene 25:3445-57. 2006
    ..0008) and apcmin/+ tumours. Preliminary in vitro data suggest ascl2 may promote progression through the G2/M cell cycle checkpoint. In summary, ascl2 is a putative regulator of proliferation that is overexpressed in intestinal neoplasia...
  6. ncbi request reprint Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
    Adrian M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    J Clin Oncol 24:217-27. 2006
    ..The aim of these retrospective subset analyses was to evaluate VEGF, thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab...
  7. ncbi request reprint EphB2 is a prognostic factor in colorectal cancer
    Adrian M Jubb
    Department of Pathology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 11:5181-7. 2005
    ..18 to 0.95 (P = 0.035). In summary, EphB2 is expressed in normal crypts, colorectal adenomas, primary cancers, and metastases. High levels of EphB2 expression are associated with a longer mean duration of survival in colorectal cancer...
  8. pmc Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours
    A M Jubb
    Department of Pathology, Genentech Inc, South San Francisco, CA94080, USA
    J Clin Pathol 57:504-12. 2004
    ....
  9. ncbi request reprint Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization
    A M Jubb
    Department of Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Pathol 200:577-88. 2003
    ..5-fold and the median VEGF-A expression was elevated 4-fold (p = 0.003) in this series of colorectal tumours. Laser imaging systems are therefore feasible for high-throughput, quantitative profiling of tissue microarrays...
  10. pmc Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
    A M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Br J Cancer 101:1749-57. 2009
    ..The aim of this study was to characterise the expression of Dll4 in colon cancer and to assess whether it is associated with markers of hypoxia and prognosis...
  11. ncbi request reprint Methylation and colorectal cancer
    A M Jubb
    Academic Unit of Pathology, Algernon Firth Building, University of Leeds, Leeds, LS2 9JT, UK
    J Pathol 195:111-34. 2001
    ..Finally, the applications of epigenetics to molecular pathology and patient diagnosis and treatment are reviewed...
  12. ncbi request reprint Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
    William L Ince
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Natl Cancer Inst 97:981-9. 2005
    ..We carried out a retrospective analysis of patients in the trial to evaluate whether mutation status of k-ras, b-raf, or p53 or P53 expression could predict which patients were more likely to respond to bevacizumab...
  13. ncbi request reprint Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF)
    Laura A Strickland
    Department of Pathology, Genentech Inc, South San Francisco, CA, USA
    J Pathol 206:466-75. 2005
    ..We suggest that PLVAP is a downstream target of VEGF signalling. This work solidifies the association between VEGF and the appearance and maintenance of fenestrations by providing a potential mechanistic link...
  14. ncbi request reprint DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility
    Adrian M Jubb
    Academic Unit of Pathology, Leeds University, Leeds, UK
    Ann N Y Acad Sci 983:251-67. 2003
    ..In addition, the authors consider the pathological utility of epigenetic testing in refining tumor staging and predicting disease recurrence...
  15. pmc Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, Weatherall Institute ofMolecular Medicine, University of Oxford, Oxford, UK
    Am J Pathol 176:2019-28. 2010
    ..002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor...
  16. ncbi request reprint Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers
    Daniel Gray
    Department of Molecular Biology, Pathology, and Bioinformatics, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 65:9751-61. 2005
    ..Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial...
  17. ncbi request reprint Quantitative in situ hybridization of tissue microarrays
    Adrian M Jubb
    Academic Unit of Pathology, University of Leeds, UK
    Methods Mol Biol 326:255-64. 2006
    ..In addition, the method includes a protocol for the development of synthetic agarose cores to control for the specificity and sensitivity of hybridization...